Westside Investment Management Inc. Increases Stock Position in Pulse Biosciences, Inc $PLSE

Westside Investment Management Inc. boosted its stake in Pulse Biosciences, Inc (NASDAQ:PLSE) by 10.5% during the 2nd quarter, Holdings Channel reports. The firm owned 64,290 shares of the company’s stock after buying an additional 6,135 shares during the quarter. Westside Investment Management Inc.’s holdings in Pulse Biosciences were worth $970,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PLSE. China Universal Asset Management Co. Ltd. purchased a new stake in Pulse Biosciences in the 1st quarter worth $218,000. PNC Financial Services Group Inc. purchased a new position in Pulse Biosciences during the 1st quarter valued at approximately $90,000. Pandora Wealth Inc. purchased a new position in Pulse Biosciences during the 1st quarter valued at approximately $828,000. Nuveen LLC purchased a new position in Pulse Biosciences during the 1st quarter valued at approximately $915,000. Finally, Quantbot Technologies LP purchased a new position in Pulse Biosciences during the 1st quarter valued at approximately $195,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PLSE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Wednesday, October 8th. Oppenheimer started coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They set an “outperform” rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Hold” and an average target price of $22.00.

Insider Activity at Pulse Biosciences

In related news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $18.49, for a total transaction of $369,800.00. Following the completion of the transaction, the insider owned 43,298 shares in the company, valued at $800,580.02. The trade was a 31.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert W. Duggan acquired 34,659 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were acquired at an average price of $14.66 per share, with a total value of $508,100.94. Following the acquisition, the director owned 47,551,200 shares in the company, valued at $697,100,592. This trade represents a 0.07% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 95,000 shares of company stock worth $1,550,380 in the last quarter. 74.60% of the stock is owned by company insiders.

Pulse Biosciences Trading Up 0.2%

Shares of PLSE opened at $16.93 on Monday. Pulse Biosciences, Inc has a twelve month low of $13.77 and a twelve month high of $25.00. The company has a market cap of $1.14 billion, a P/E ratio of -16.12 and a beta of 1.79. The company’s fifty day simple moving average is $17.06 and its 200-day simple moving average is $16.52.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.